Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Why your retirement fund might soon include cryptocurrency 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Investors Brace for Market Moves as Trump Begins Second Term 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge 
Gold Prices Rise as Markets Await Trump’s Policy Announcements 
Tech Stocks Rally in Asia-Pacific as Dollar Remains Resilient 
Why the Middle East is being left behind by global climate finance plans 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
